Department of Surgery, National Center for Global Health and Medicine, Tokyo, Japan.
Department of Gastroenterology, The Research Center for Hepatitis and Immunology, Research Institute, National Center for Global Health and Medicine, Chiba, Japan.
Ann Surg Oncol. 2021 Sep;28(9):5373-5381. doi: 10.1245/s10434-020-09550-y. Epub 2021 Jan 15.
A previous study conducted a transcriptome analysis of paired normal and esophageal squamous cell carcinoma (ESCC) tissue samples. The results showed that the expression of serine protease 27 (PRSS27) was perturbed in tumor samples. Hence, this retrospective study aimed to validate the prognostic significance of PRSS27 in patients with preoperative treatment for ESCC.
We enrolled 86 patients who received preoperative treatment before esophagectomy for ESCC. The expression of PRSS27 in resected ESCC and biopsy tissue samples obtained before preoperative treatment was evaluated via immunostaining, and its relationship with clinicopathological features and prognosis was analyzed.
In normal esophageal mucosa tissue samples, PRSS27 was expressed in the cytoplasm of spinous cells in the suprabasal layer and basal cells in the basal layer. Of 64 resected ESCC tissue samples, 35 (54.7%) expressed PRSS27 and 29 (45.3%) did not. Moreover, ectopic nuclear expression of PRSS27 was observed. Based on multivariate analysis, PRSS27 expression in resected tumor samples was a predictor of poor prognosis. In cases in which PRSS27 expression was observed in biopsy samples, patients with PRSS27-negative resected tumors had a better postoperative prognosis than those with PRSS27-positive resected tumors.
PRSS27 expression in resected ESCC tissue samples is a poor prognostic factor in ESCC patients with preoperative treatment. Furthermore, conversion of PRSS27 expression from positive in biopsy samples to negative in resected tumor samples is a predictor of good prognosis in these patients. Hence, PRSS27 status is an effective tool for decision making regarding adjuvant treatment in ESCC patients.
先前的一项研究对配对的正常食管鳞状细胞癌（ESCC）组织样本进行了转录组分析。结果表明，肿瘤样本中丝氨酸蛋白酶 27（PRSS27）的表达受到干扰。因此，本回顾性研究旨在验证 PRSS27 在接受术前治疗的 ESCC 患者中的预后意义。
我们纳入了 86 例接受术前治疗后行 ESCC 切除术的患者。通过免疫组化评估 PRSS27 在切除的 ESCC 和术前治疗前获得的活检组织样本中的表达，并分析其与临床病理特征和预后的关系。
在正常食管黏膜组织样本中，PRSS27 表达于棘细胞的胞质中，在上皮的棘层和基底层。在 64 例切除的 ESCC 组织样本中，35 例（54.7%）表达 PRSS27，29 例（45.3%）不表达。此外，观察到 PRSS27 的核异位表达。基于多变量分析，切除肿瘤样本中的 PRSS27 表达是预后不良的预测因子。在活检样本中观察到 PRSS27 表达的情况下，PRSS27 阴性切除肿瘤患者的术后预后优于 PRSS27 阳性切除肿瘤患者。
术前治疗的 ESCC 患者切除的 ESCC 组织样本中 PRSS27 的表达是预后不良的因素。此外，活检样本中 PRSS27 表达从阳性转为切除肿瘤样本中的阴性是这些患者预后良好的预测因子。因此，PRSS27 状态是 ESCC 患者辅助治疗决策的有效工具。
